UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 231

Sortiert nach

Best Practices to Maximize the Use and Reuse of Quantitative and Systems Pharmacology Models: Recommendations From the United Kingdom Quantitative and Systems Pharmacology Network

CPT: pharmacometrics and systems pharmacology, 2019-05, Vol.8 (5), p.259-272

2019

Volltextzugriff (PDF)

Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study

Clinical cancer research, 2021-10, Vol.27 (19), p.5213-5224

2021

Volltextzugriff (PDF)

Characterization of the disposition of fostamatinib in Japanese subjects including pharmacokinetic assessment in dry blood spots: results from two phase I clinical studies

European journal of clinical pharmacology, 2016-01, Vol.72 (1), p.61-71

2016

Volltextzugriff (PDF)

Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER + Invasive Breast Cancer (STAKT)

Clinical cancer research, 2020-04, Vol.26 (7), p.1574-1585

2020

Volltextzugriff (PDF)

Industry Perspective on Using MIDD for Pediatric Studies Requiring Integration of Ontogeny

Journal of clinical pharmacology, 2019-09, Vol.59 (S1), p.S112-S119

2019

Volltextzugriff (PDF)

Cost effectiveness analyses of pharmacological treatments in heart failure

Frontiers in pharmacology, 2022-09, Vol.13, p.919974-919974

2022

Volltextzugriff (PDF)

Harnessing formulation and clinical pharmacology knowledge for efficient pediatric drug development: Overview and discussions from M-CERSI pediatric formulation workshop 2019

European journal of pharmaceutics and biopharmaceutics, 2021-07, Vol.164, p.66-74

2021

Volltextzugriff (PDF)

Artificial Intelligence and Machine Learning Applied at the Point of Care

Frontiers in pharmacology, 2020-06, Vol.11, p.759

2020

Volltextzugriff (PDF)

Pediatric oncology drug development and dosage optimization

Frontiers in oncology, 2024-01, Vol.13, p.1235947-1235947

2024

Volltextzugriff (PDF)

Editorial: Model-informed drug development and evidence-based translational pharmacology

Frontiers in pharmacology, 2022-12, Vol.13, p.1086551-1086551

2022

Volltextzugriff (PDF)

Epstein-Barr Virus Reactivation After Paediatric Haematopoietic Stem Cell Transplantation: Risk Factors and Sensitivity Analysis of Mathematical Model

Frontiers in immunology, 2022-07, Vol.13, p.903063

2022

Volltextzugriff (PDF)

V2ACHER: Visualization of complex trial data in pharmacometric analyses with covariates

CPT: pharmacometrics and systems pharmacology, 2021-09, Vol.10 (9), p.1092-1106

2021

Volltextzugriff (PDF)

How is the Pharmaceutical Industry Structured to Optimize Pediatric Drug Development? Existing Pediatric Structure Models and Proposed Recommendations for Structural Enhancement

Therapeutic innovation & regulatory science, 2020-09, Vol.54 (5), p.1076-1084

2020

Volltextzugriff (PDF)

Supporting Prospective Pregnancy Trials via Modeling and Simulation: Lessons From the Past and Recommendations for the Future

Journal of clinical pharmacology, 2023-06, Vol.63 (S1), p.S51-S61

2023

Volltextzugriff (PDF)

Correction to: How is the Pharmaceutical Industry Structured to Optimize Pediatric Drug Development? Existing Pediatric Structure Models and Proposed Recommendations for Structural Enhancement

Therapeutic innovation & regulatory science, 2020-09, Vol.54 (5), p.1085-1085

2020

Volltextzugriff (PDF)

Predictive Performance of Physiologically Based Pharmacokinetic (PBPK) Modeling of Drugs Extensively Metabolized by Major Cytochrome P450s in Children

Clinical pharmacology and therapeutics, 2018-07, Vol.104 (1), p.188-200

2018

Volltextzugriff (PDF)

The design and analysis of parallel experiments to produce structurally identifiable models

Journal of pharmacokinetics and pharmacodynamics, 2013-02, Vol.40 (1), p.93-100

2013

Volltextzugriff (PDF)

Moving Toward a Question‐Centric Approach for Regulatory Decision Making in the Context of Drug Assessment

Clinical pharmacology and therapeutics, 2023-07, Vol.114 (1), p.41-50

2023

Volltextzugriff (PDF)

Concentration‐QT modelling shows no evidence of clinically significant QT interval prolongation with capivasertib at expected therapeutic concentrations

British journal of clinical pharmacology, 2022-02, Vol.88 (2), p.858-864

2022

Volltextzugriff (PDF)

A meta-analysis of tumour response and relapse kinetics based on 34,881 patients: A question of cancer type, treatment and line of treatment

European journal of cancer (1990), 2021-06, Vol.150, p.42-52

2021

Volltextzugriff (PDF)

Use of pharmacodynamic modeling for Bayesian information borrowing in pediatric clinical trials

Journal of biopharmaceutical statistics, 2023-11, Vol.33 (6), p.726-736

2023

Volltextzugriff (PDF)

Understanding Hematological Toxicities Using Mathematical Modeling

Clinical pharmacology and therapeutics, 2018-10, Vol.104 (4), p.644-654

2018

Volltextzugriff (PDF)

Pediatric Extrapolation in Type 2 Diabetes: Future Implications of a Workshop

Clinical pharmacology and therapeutics, 2020-07, Vol.108 (1), p.29-39

2020

Volltextzugriff (PDF)

Forward and reverse translational approaches to predict efficacy of neutralizing respiratory syncytial virus (RSV) antibody prophylaxis

EBioMedicine, 2021-11, Vol.73, p.103651-103651, Article 103651

2021

Volltextzugriff (PDF)

V 2 ACHER: Visualization of complex trial data in pharmacometric analyses with covariates

CPT: pharmacometrics and systems pharmacology, 2021-09, Vol.10 (9), p.1092-1106

2021

Volltextzugriff (PDF)

1 – 25 von 231

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(223)
Mit Volltextzugriff
(216)

Publikationsform

Artikel
(230)
Bücher
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Best Practices to Maximize the Use and Reuse of Quantitative and Systems Pharmacology Models: Recommendations From the United Kingdom Quantitative and Systems Pharmacology Network

Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study

Characterization of the disposition of fostamatinib in Japanese subjects including pharmacokinetic assessment in dry blood spots: results from two phase I clinical studies

Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER + Invasive Breast Cancer (STAKT)

Industry Perspective on Using MIDD for Pediatric Studies Requiring Integration of Ontogeny

Cost effectiveness analyses of pharmacological treatments in heart failure

Harnessing formulation and clinical pharmacology knowledge for efficient pediatric drug development: Overview and discussions from M-CERSI pediatric formulation workshop 2019

Artificial Intelligence and Machine Learning Applied at the Point of Care

Pediatric oncology drug development and dosage optimization

Editorial: Model-informed drug development and evidence-based translational pharmacology

Epstein-Barr Virus Reactivation After Paediatric Haematopoietic Stem Cell Transplantation: Risk Factors and Sensitivity Analysis of Mathematical Model

V2ACHER: Visualization of complex trial data in pharmacometric analyses with covariates

How is the Pharmaceutical Industry Structured to Optimize Pediatric Drug Development? Existing Pediatric Structure Models and Proposed Recommendations for Structural Enhancement

Supporting Prospective Pregnancy Trials via Modeling and Simulation: Lessons From the Past and Recommendations for the Future

Correction to: How is the Pharmaceutical Industry Structured to Optimize Pediatric Drug Development? Existing Pediatric Structure Models and Proposed Recommendations for Structural Enhancement

Predictive Performance of Physiologically Based Pharmacokinetic (PBPK) Modeling of Drugs Extensively Metabolized by Major Cytochrome P450s in Children

The design and analysis of parallel experiments to produce structurally identifiable models

Moving Toward a Question‐Centric Approach for Regulatory Decision Making in the Context of Drug Assessment

Concentration‐QT modelling shows no evidence of clinically significant QT interval prolongation with capivasertib at expected therapeutic concentrations

A meta-analysis of tumour response and relapse kinetics based on 34,881 patients: A question of cancer type, treatment and line of treatment

Use of pharmacodynamic modeling for Bayesian information borrowing in pediatric clinical trials

Understanding Hematological Toxicities Using Mathematical Modeling

Pediatric Extrapolation in Type 2 Diabetes: Future Implications of a Workshop

Forward and reverse translational approaches to predict efficacy of neutralizing respiratory syncytial virus (RSV) antibody prophylaxis

V 2 ACHER: Visualization of complex trial data in pharmacometric analyses with covariates

Suchergebnisse filtern